Bio2 Technologies (Woburn, Mass.) has raised about $4.3 million as it continues with a clinical trial of its Vitrium resorbable orthopedic biomaterial for musculoskeletal surgery.
Bio2 had sought to raise $6.5 million in the funding round, according to a Form D filed Sept. 6 with the U.S. Securities and Exchange Commission.
Made of bioactive glass, Vitrium is porous, load-bearing, osteoconductive and bioactive, according to Bio2 Technologies.